AAIC 2022

Featured update

A new way to guide patient care at AAIC 2022

When it comes to Alzheimer’s disease, early detection is essential to better care.

Mayo Clinic Laboratories offers an innovative testing solution for the early detection of Alzheimer's disease. Our evaluation, which uses CSF biomarkers to achieve a high concordance with an amyloid positron emission tomography (PET) scan, delivers faster results and provides new hope for correctly diagnosing and managing Alzheimer's disease along with other dementias.

Are you attending AAIC 2022? Visit with Mayo Clinic Laboratories’ neurology team at Booth 100.




  • To learn how Mayo Clinic’s Alzheimer’s disease testing provides definitive answers to guide better treatment.

More information on AAIC 2022 and Alzheimer’s disease testing at Mayo Clinic is available here.

See you at AAIC 2022.

Meghann Southwick

Meghann Southwick is a marketing specialist for Mayo Clinic Laboratories. She has worked at Mayo Clinic since 2021.